A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of HRS-1893 in Healthy Participants
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY
The purpose of this study is to assess the safety and PK characteristics of a single oral dose of HRS-1893 in healthy voluunters.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 55
Healthy Volunteers: t
View:
• Healthy white participants;
• Ability to understand the trial procedures and possible adverse events, volunteer to participate in the trial, and provide written informed consent, be able to comply with all the requirements, and able to complete the study.
• Male aged between 18 to 55 years of age (inclusive)
• Women with body weight ≥ 45.0 kg, men with body weight ≥ 50.0 kg, body mass index (BMI) between 19.0 and 30.0 kg/m2 (inclusive) at screening.
• Negative pregnancy test for women of childbearing potential (WOCBP) at baseline. Men and WOCBP must agree to take highly effective contraceptive methods
Locations
Other Locations
Australia
Linear Clinical Research
RECRUITING
Nedlands
Contact Information
Primary
Kathy You
kathyyou@atridia.com
+61 02 9299 0433
Backup
Eimy Minowa
eimy.minowa@atridia.com
+61 432223162
Time Frame
Start Date: 2025-06-25
Estimated Completion Date: 2025-09-30
Participants
Target number of participants: 20
Treatments
Experimental: HRS-1893 Dose level 1
Single oral low dose of HRS-1893 (dose level 1)
Experimental: HRS-1893 Dose level 2
Single oral high dose of HRS-1893 (dose level 2)
Related Therapeutic Areas
Sponsors
Leads: Atridia Pty Ltd.